Table 2—

Adverse events recorded during the 4-week treatment period with NVP DPP728 at 100 mg t.i.d. or 150 mg b.i.d. or with placebo in subjects with type 2 diabeteslegend

NVP DPP728
Placebo (N = 32)
100 mg t.i.d. (n = 30)150 mg b.i.d. (n = 31)Total active (n = 61)
Pruritus2350
Diarrhea3141
Nasopharyngitis1340
Hypoglycemia1341
Dizziness0442
Headache0331
Vertigo2020
Nausea1120
Depression1120
Urinary frequency1121
Night sweats1120
Constipation1010
Hiatal hernia0110
Weakness0110
Stye1010
Decreased appetite0111
Myalgia1010
Hypertonia0110
Paresthesia0110
Nephrotic syndrome0110
Hoarseness0110
Allergic rhinitis1010
Increased sweating0110
Tremor0110
  • legend

    legend Data are n. All events recorded in the active treatment groups are shown. Eight further adverse events occurring only in the placebo arm have been omitted.